<DOC>
	<DOCNO>NCT01090960</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I study evaluate safety , tolerability , pharmacokinetics escalate oral dos GDC-0068 administer patient incurable , locally advanced metastatic solid malignancy progress failed respond least one prior regimen standard therapy . This study expect enroll approximately 39 57 patient approximately two site Spain .</brief_summary>
	<brief_title>A Study Evaluating Safety Tolerability GDC-0068 Patients With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically document , incurable , locally advanced metastatic solid tumor standard therapy either exist proven ineffective intolerable . Evaluable measurable disease Life expectancy &gt; = 12 week Adequate hematologic organ function within 14 day initiation GDC0068 Documented willingness use effective mean contraception ( e.g. , abstinence , hormonal double barrier method , surgically sterilized partner ) men woman participate study History Type 1 2 diabetes mellitus require regular medication Grade &gt; 2 hypercholesterolemia hypertriglyceridemia Malabsorption syndrome condition would interfere enteral absorption Leptomeningeal disease manifestation current malignancy Known untreated malignancy brain spinal cord , treat brain metastasis radiographically stable &gt; = 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>